PMID- 25753908
OWN - NLM
STAT- MEDLINE
DCOM- 20160126
LR  - 20220311
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 54
IP  - 5
DP  - 2015
TI  - The risk of tuberculosis in patients with psoriasis treated with anti-tumor 
      necrosis factor agents.
PG  - 594-9
LID - 10.1111/ijd.12628 [doi]
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) antagonist treatment is 
      associated with 1.6 to 27 times higher risk of tuberculosis (TB). OBJECTIVE: To 
      find TB incidence of psoriasis patients treated with TNF- alpha antagonists and 
      define risk factors related with this condition in a country with moderately high 
      risk of TB. METHODS: Three hundred seventy psoriasis patients treated by anti-TNF 
      agents in four referral centers were included. The data on the characteristics of 
      the patients, TB history, tuberculosis skin test results, anti-TNF agent type and 
      exposure time, localization of TB, and isoniazide prophylaxis state were 
      analyzed. RESULTS: Four patients (1.08%) developed TB, three pulmonary and one 
      gastrointestinal, 2-23 months after initiating anti-TNF agents. Other than the 
      patient with gastrointestinal TB, who was using methotrexate and corticosteroid 
      concomitantly, none had contributing risk factors for TB. Two patients developed 
      pulmonary TB in spite of chemoprophylaxis. Three patients with pulmonary TB 
      completely recovered following antiTB treatment whereas patients with 
      gastroinrestinal TB developed renal failure. LIMITATIONS: The major limitation of 
      the study is the lack of a diseased control group, which enables us to compare 
      the risk of psoriatics with that of patients having other inflammatory diseases. 
      CONCLUSION: Tuberculosis is a rare but a severe complication of anti-TNF 
      treatment and may develop in spite of chemoprophylaxis. The risk of TB in 
      psoriasis patients in the present study is comparable to literature mostly based 
      on rheumatology patients.
CI  - (c) 2015 The International Society of Dermatology.
FAU - Ergun, Tulin
AU  - Ergun T
AD  - Department of Dermatology, Marmara University School of Medicine, Istanbul, 
      Turkey.
FAU - Seckin, Dilek
AU  - Seckin D
FAU - Baskan Bulbul, Emel
AU  - Baskan Bulbul E
FAU - Onsun, Nahide
AU  - Onsun N
FAU - Ozgen, Zuleyha
AU  - Ozgen Z
FAU - Unalan, Pemra
AU  - Unalan P
FAU - Alpsoy, Erkan
AU  - Alpsoy E
FAU - Karakurt, Sait
AU  - Karakurt S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150306
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chemoprevention
MH  - Child
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*drug therapy
MH  - Risk Assessment
MH  - Risk Factors
MH  - Tuberculosis/*chemically induced/epidemiology/prevention & control
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Young Adult
EDAT- 2015/03/11 06:00
MHDA- 2016/01/27 06:00
CRDT- 2015/03/11 06:00
PHST- 2015/03/11 06:00 [entrez]
PHST- 2015/03/11 06:00 [pubmed]
PHST- 2016/01/27 06:00 [medline]
AID - 10.1111/ijd.12628 [doi]
PST - ppublish
SO  - Int J Dermatol. 2015;54(5):594-9. doi: 10.1111/ijd.12628. Epub 2015 Mar 6.